Vorherige Seite
    Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April... (32017R0745)
    1 - 2347 - 348
    Nächste Seite
    EU - Rechtsakte: 15 Environment, consumers and health protection
    In addition, for devices placed on the market in a sterile condition, and only for those aspects of the manufacturing process designed to secure and maintain sterility, the manufacturer shall apply the provisions of Sections 6 and 7.
    13.   The manufacturer shall undertake to institute and keep up to date a post-market surveillance plan, including a PMCF plan, and the procedures ensuring compliance with the obligations of the manufacturer resulting from the provisions on vigilance and post-market surveillance system set out in Chapter VII.
    14.   The notified body shall carry out the appropriate examinations and tests in order to verify the conformity of the device with the requirements of the Regulation by examining and testing every product as specified in Section 15.
    The examinations and tests referred to in the first paragraph of this Section shall not apply to aspects of the manufacturing process designed to secure sterility.

    15.   Verification by examination and testing of every product

    15.1.   Every device shall be examined individually and the appropriate physical or laboratory tests as defined in the relevant standard or standards referred to in Article 8, or equivalent tests and assessments, shall be carried out in order to verify, where appropriate, the conformity of the devices with the type described in the EU type-examination certificate and with the requirements of this Regulation which apply to them.
    15.2.   The notified body shall affix, or have affixed, its identification number to each approved device and shall draw up an EU product verification certificate relating to the tests and assessments carried out.
    16.   Batch verification in the case of devices incorporating, as an integral part, a medicinal substance which, if used separately, would be considered to be a medicinal product derived from human blood or human plasma referred to in Article 1(8).
    Upon completing the manufacture of each batch of devices that incorporate, as an integral part, a medicinal substance which, if used separately, would be considered to be a medicinal product derived from human blood or human plasma referred to in the first subparagraph of Article 1(8), the manufacturer shall inform the notified body of the release of the batch of devices and send it the official certificate concerning the release of the batch of human blood or plasma derivative used in the device, issued by a Member State laboratory or a laboratory designated for that purpose by a Member State in accordance with Article 114(2) of Directive 2001/83/EC.

    17.   Administrative provisions

    The manufacturer or its authorised representative shall, for a period ending no sooner than 10 years, and in the case of implantable devices no sooner than 15 years, after the last device has been placed on the market, keep at the disposal of the competent authorities:
    — the EU declaration of conformity,
    — the documentation referred to in Section 12,
    — the certificate referred to in Section 15.2, and
    — the EU type-examination certificate referred to in Annex X.
    Section 8 of Annex IX shall apply.

    18.   Application to class IIa devices

    Markierungen
    Leseansicht
    Verwendung von Cookies.

    Durch die Nutzung dieser Website akzeptieren Sie automatisch, dass wir Cookies verwenden. Cookie-Richtlinie

    Akzeptieren